Immunogen, Inc.

NASDAQ:IMGN   10:35:57 AM EDT
5.75
-0.12 (-2.04%)
Other Pre-Announcement

ImmunoGen Reports Recent Progress And Second Quarter 2022 Financial Results

Published: 07/29/2022 10:49 GMT
Immunogen, Inc. (IMGN) - Immunogen Reports Recent Progress and Second Quarter 2022 Financial Results.
Total Revenues Were $14.2 Million for Quarter Ended June 30, 2022 Compared to $16.9 Million for Quarter Ended June 30, 2021.
Net Loss for Q2 of 2022 Was $62.0 Million, Or $0.24 per Basic and Diluted Share.
Financial Guidance for 2022 Remains Unchanged.
Financial Guidance for 2022 Remains Unchanged.
Expects That Its Current Cash, Combined With Anticipated Product and Collaboration Revenues, Will Fund Operations Into 2024.
Q2 Earnings per Share View $-0.21, Revenue View $16.2 Million -- Refinitiv Ibes Data (analyst estimates).